Table 2.
Change from baseline to Week 12 in SF-36 bodily pain, social functioning, and role-physical domains in eptinezumab-treated ≥ 75% and ≥ 50–< 75% migraine responders
| Eptinezumab 100 mg | Eptinezumab 300 mg | Eptinezumab Pooled | ||||
| PROMISE-1 (EM) |
≥ 50–< 75% N = 61 |
≥ 75% N = 49 |
≥ 50–< 75% N = 59 |
≥ 75% N = 66 |
≥ 50–< 75% N = 120 |
≥ 75% N = 115 |
| Bodily pain | ||||||
| Baseline, mean (SD) | 45.8 (8.88) | 46.2 (9.95) | 46.5 (9.71) | 48.5 (9.30) | 46.1 (9.27) | 47.5 (9.60) |
| Week 12, mean (SD) | 51.2 (8.99) | 52.7 (8.26) | 52.5 (7.86) | 54.7 (7.20) | 51.8 (8.46) | 53.9 (7.70) |
| Change from baseline, mean (SD) | 5.8 (8.24) | 6.7 (7.83) | 6.1 (8.19) | 5.9 (7.66) | 5.9 (8.18) | 6.2 (7.71) |
| Social functioning | ||||||
| Baseline, mean (SD) | 48.6 (9.37) | 50.6 (8.22) | 50.4 (8.98) | 51.4 (8.06) | 49.5 (9.19) | 51.1 (8.10) |
| Week 12, mean (SD) | 51.5 (8.97) | 53.9 (5.08) | 52.8 (6.97) | 53.9 (6.26) | 52.1 (8.07) | 53.9 (5.77) |
| Change from baseline, mean (SD) | 3.3 (9.96) | 3.2 (7.49) | 2.6 (8.26) | 2.2 (7.14) | 3.0 (9.15) | 2.6 (7.28) |
| Role-physical | ||||||
| Baseline, mean (SD) | 49.8 (7.61) | 49.1 (8.90) | 49.7 (7.75) | 50.1 (7.91) | 49.8 (7.64) | 49.7 (8.32) |
| Week 12, mean (SD) | 51.2 (6.92) | 53.8 (6.57) | 52.8 (5.71) | 54.2 (5.04) | 52.0 (6.39) | 54.0 (5.72) |
| Change from baseline, mean (SD) | 1.5 (7.86) | 4.7 (7.91) | 3.1 (6.56) | 3.9 (7.50) | 2.3 (7.28) | 4.3 (7.65) |
| PROMISE-2 (CM) |
≥ 50–< 75% N = 110 |
≥ 75% N = 95 |
≥ 50–< 75% N = 99 |
≥ 75% N = 116 |
≥ 50–< 75% N = 209 |
≥ 75% N = 211 |
| Bodily pain | ||||||
| Baseline, mean (SD) | 40.6 (10.25) | 40.1 (9.60) | 40.5 (8.97) | 40.1 (9.40) | 40.5 (9.64) | 40.1 (9.47) |
| Week 12, mean (SD) | 45.8 (8.81) | 49.2 (8.14) | 46.8 (7.80) | 50.2 (7.57) | 46.3 (8.35) | 49.7 (7.82) |
| Change from baseline, mean (SD) | 5.1 (8.22) | 9.4 (9.66) | 6.2 (8.37) | 10.1 (9.21) | 5.6 (8.29) | 9.8 (9.39) |
| Social functioning | ||||||
| Baseline, mean (SD) | 43.7 (9.36) | 42.6 (10.82) | 44.0 (10.05) | 43.0 (9.65) | 43.8 (9.67) | 42.8 (10.17) |
| Week 12, mean (SD) | 49.1 (7.42) | 51.1 (6.83) | 49.0 (7.48) | 51.1 (7.42) | 49.1 (7.43) | 51.1 (7.15) |
| Change from baseline, mean (SD) | 5.3 (7.41) | 8.4 (9.50) | 5.5 (7.68) | 8.0 (9.14) | 5.4 (7.52) | 8.2 (9.28) |
| Role-physical | ||||||
| Baseline, mean (SD) | 42.5 (8.52) | 42.3 (9.04) | 42.4 (9.15) | 42.2 (8.72) | 42.4 (8.80) | 42.2 (8.84) |
| Week 12, mean (SD) | 48.1 (7.61) | 49.4 (6.79) | 48.7 (7.51) | 50.7 (6.93) | 48.4 (7.55) | 50.1 (6.88) |
| Change from baseline, mean (SD) | 5.5 (7.05) | 7.1 (9.74) | 6.5 (7.74) | 8.6 (8.67) | 6.0 (7.38) | 7.9 (9.17) |
A ≥ 75% or ≥ 50–< 75% migraine responder was defined as a patient who achieved a ≥ 75% or ≥ 50–< 75% reduction in mean monthly migraine days over Weeks 1–12. CM, chronic migraine; EM, episodic migraine; SD, standard deviation; SF-36, 36-item Short-Form Health Survey (v2.0)